- Report
- June 2021
- 197 Pages
Latin America
From €3566EUR$4,000USD£3,095GBP
- Report
- October 2023
- 253 Pages
Global
From €4414EUR$4,950USD£3,830GBP
- Report
- September 2024
- 187 Pages
Global
From €4012EUR$4,500USD£3,482GBP
- Report
- July 2024
- 150 Pages
Global
From €3344EUR$3,750USD£2,902GBP
- Report
- January 2024
- 200 Pages
Global
From €3700EUR$4,150USD£3,211GBP
- Report
- June 2023
- 115 Pages
Global
From €4012EUR$4,500USD£3,482GBP
- Report
- May 2024
- 100 Pages
Africa
From €1783EUR$2,000USD£1,548GBP
- Report
- April 2024
- 80 Pages
China
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
France
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
Germany
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
India
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1337EUR$1,500USD£1,161GBP
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1337EUR$1,500USD£1,161GBP
- Report
- April 2024
- 80 Pages
United States
From €1337EUR$1,500USD£1,161GBP
- Report
- July 2024
- 158 Pages
Global
From €3221EUR$3,613USD£2,795GBP
€3789EUR$4,250USD£3,289GBP
- Report
- October 2023
- 150 Pages
Global
From €3433EUR$3,850USD£2,979GBP
€4324EUR$4,850USD£3,753GBP
- Report
- April 2022
- 113 Pages
Europe
From €1337EUR$1,500USD£1,161GBP
- Report
- May 2025
Saudi Arabia
From €1650EUR$1,850USD£1,431GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more